TRIB3 and ovarian carcinoma: The expression of TRIB3 is higher in breast cancer (Wennemers et al., 2011), ovarian cancer (Wang et al., 2020), lung cancer (Zhang X. et al., 2019), and colorectal cancer (Hua et al., 2019), and outcomes are poor.